Hypoxia-responsive self-assembled nanoparticles for reprogramming tumor-associated macrophages into an anti-tumor M1 phenotype in breast cancer
Source abstract
Abstract
The tumor microenvironment is characterized by hypoxia, resulting mainly from aberrant vascularization and insufficient blood perfusion. Under such hypoxic conditions, tumor-associated macrophages (TAMs) preferentially polarize toward an immunosuppressive M2-like phenotype, which promotes immune evasion and accelerates tumor progression. Reprogramming these M2-like TAMs into an anti-tumor M1 phenotype represents a promising therapeutic strategy, yet it remains a substantial challenge. In this study, we developed nanoparticles functionalized with mannose and an MMP-2-responsive PLGVRGD peptide. These nanoparticles undergo self-assembly in the presence of matrix metalloproteinase-2 (MMP-2), which is highly expressed in hypoxic tumor regions. The high-density mannose residues on the nanoparticle surface facilitate efficient binding to M2-like TAMs and promote their repolarization to the M1 phenotype. Moreover, the resulting system exhibits enhanced tumor tissue penetration and effectively reverses the immunosuppressive tumor microenvironment, supporting its potential as a targeted nanotherapeutic strategy for breast cancer.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Immune cells in cancer · Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (64)
Show source-provided references
1. Role of hypoxia in cancer therapy by regulating the tumor microenvironment10.1186/s12943-019-1089-9 ↗
2. Recent advancements of nanotechnology-based strategies for overcoming tumor microenvironment hypoxia10.31083/j.fbl2705145 ↗
3. Normalization of the vasculature for treatment of cancer and other diseases10.1152/physrev.00038.2010 ↗
4. Hypoxia accelerates the progression of angiosarcoma through the regulation of angiosarcoma cells and tumor microenvironment10.1016/j.jdermsci.2019.01.005 ↗
5. Hypoxia-induced myeloid derived growth factor promotes hepatocellular carcinoma progression through remodeling tumor microenvironment10.7150/thno.49327 ↗
6. Responsive role of nanomedicine in the tumor microenvironment and cancer drug resistance10.2174/0929867329666220922111336 ↗
7. Hypoxia-inducible factor-dependent ADAM12 expression mediates breast cancer invasion and metastasis10.1073/pnas.2020490118 ↗
8. Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape10.1186/s13045-022-01292-6 ↗
9. Aspects of the tumor microenvironment involved in immune resistance and drug resistance10.3389/fimmu.2021.656364 ↗
10. Macrophage polarization states in the tumor microenvironment10.3390/ijms22136995 ↗
11. The hypoxia-driven crosstalk between tumor and tumor-associated macrophages: mechanisms and clinical treatment strategies10.1186/s12943-022-01645-2 ↗
12. Hypoxic tumor-derived exosomal miR-301a mediates M2 macrophage polarization via PTEN/PI3Kγ to promote pancreatic cancer metastasis10.1158/0008-5472.CAN-17-3841 ↗
13. MicroRNA-301a inhibition enhances the immunomodulatory functions of adipose-derived mesenchymal stem cells by induction of macrophage M2 polarization10.1177/2058738420966092 ↗
14. Correction: hypoxic tumor-derived exosomal miR-301a mediates M2 macrophage polarization via PTEN/PI3Kγ to promote pancreatic cancer metastasis10.1158/0008-5472.CAN-19-3872 ↗
15. Hypoxia-driven tumor stromal remodeling and immunosuppressive microenvironment in scirrhous HCC10.1097/HEP.0000000000000599 ↗
16. Ginseng-derived nanoparticles alter macrophage polarization to inhibit melanoma growth10.1186/s40425-019-0817-4 ↗
17. Targeting tumor-associated macrophages in the tumor microenvironment10.3892/ol.2020.12097 ↗
18. Tumor microenvironment-responsive delivery nanosystems reverse immunosuppression for enhanced CO gas/immunotherapy
19. Oxygen-carrying nanoplatform to reprogram tumor immunosuppressive microenvironment and enhance photothermal-immunotherapy
20. Bioengineered nanogels for cancer immunotherapy10.1039/D2CS00247G ↗
21. Therapeutic copolymer from salicylic acid and l-Phenylalanine as a nanosized drug carrier for orthotopic breast cancer with lung metastasis10.1021/acsami.3c08608 ↗
22. Stimuli-responsive nanocarriers for drug delivery10.1038/nmat3776 ↗
23. Nano based drug delivery systems: recent developments and future prospects10.1186/s12951-018-0392-8 ↗
24. Deformable nanocarriers for enhanced drug delivery and cancer therapy
25. Tumor microenvironment as a therapeutic target in cancer10.1016/j.pharmthera.2020.107753 ↗
26. Tumor microenvironment10.3390/medicina56010015 ↗
27. Macrophages and metabolism in the tumor microenvironment10.1016/j.cmet.2019.06.001 ↗
28. Pathological environment directed in situ peptidic supramolecular assemblies for nanomedicines10.1088/1748-605X/abc2e9 ↗
29. Near-infrared laser-driven in situ self-assembly as a general strategy for deep tumor therapy10.1021/acs.nanolett.8b03174 ↗
30. Enzyme-mediated in situ self-assembly promotes in vivo bioorthogonal reaction for pretargeted multimodality imaging10.1002/anie.202103307 ↗
31. In situ orderly self-assembly strategy affording NIR-II-J-aggregates for in vivo imaging and surgical navigation10.1038/s41467-023-37586-7 ↗
32. Hypoxia-triggered in situ self-assembly of a charge switchable azo polymer with AIEgens for tumor imaging10.1021/acsmacrolett.1c00183 ↗
33. Nanomedicine in cancer therapy10.1038/s41392-023-01536-y ↗
34. Current perspectives and trend of nanomedicine in cancer: a review and bibliometric analysis10.1016/j.jconrel.2022.10.023 ↗
35. In situ self-assembly for cancer therapy and imaging10.1038/s41578-023-00589-3 ↗
36. Self-adaptive nanoassembly enabling turn-on hypoxia illumination and periphery/center closed-loop tumor eradication
37. Immunostimulation of tumor microenvironment by targeting tumor-associated macrophages with hypoxia-responsive nanocomplex for enhanced anti-tumor therapy10.1016/j.jconrel.2022.01.021 ↗
38. New opportunities for immunomodulation of the tumour microenvironment using chemical tools10.1039/D2CS00486K ↗
39. Rediscovery of mononuclear phagocyte system blockade for nanoparticle drug delivery10.1038/s41467-024-48838-5 ↗
40. Fluorinated PLGA-PEG-Mannose nanoparticles for tumor-associated macrophage detection by optical imaging and MRI10.3389/fmed.2021.712367 ↗
41. Macrophage-reprogramming upconverting nanoparticles for enhanced TAM-mediated antitumor therapy of hypoxic breast cancer10.1016/j.jconrel.2023.07.009 ↗
42. Targeted delivery of chlorogenic acid by mannosylated liposomes to effectively promote the polarization of TAMs for the treatment of glioblastoma
43. Regulation of M1-type and M2-type macrophage polarization in RAW264.7 cells by Galectin-910.3892/mmr.2017.7719 ↗
44. M2-like macrophages are responsible for collagen degradation through a mannose receptor-mediated pathway10.1083/jcb.201301081 ↗
45. Mannose-decorated hybrid nanoparticles for enhanced macrophage targeting
46. Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses10.1126/scitranslmed.aax6337 ↗
47. Hypoxia-induced scleral HIF-2α upregulation contributes to rises in MMP-2 expression and myopia development in mice10.1167/iovs.63.8.2 ↗
48. p21(WAF1/Cip1) regulation by hYSK1 activates SP-1 transcription factor and increases MMP-2 expression under hypoxic conditions10.3390/ijms20020310 ↗
49. Targeted imaging of CD206 expressing tumor-associated M2-like macrophages using mannose-conjugated antibiofouling magnetic iron oxide nanoparticles10.1021/acsabm.0c00368 ↗
50. Mannose attenuates colitis-associated colorectal tumorigenesis by targeting tumor-associated macrophages10.15430/JCP.2022.27.1.31 ↗
51. MMP-responsive nanomaterials10.1039/D3BM00840A ↗
52. Reprogramming hypoxic tumor‐associated macrophages by nanoglycoclusters for boosted cancer immunotherapy10.1002/adma.202211332 ↗
53. Macrophages in immunoregulation and therapeutics
54. Mannose receptor modulates macrophage polarization and allergic inflammation through miR-511-3p10.1016/j.jaci.2017.04.049 ↗
55. Targeting of tumor-associated macrophages made possible by PEG-sheddable, mannose-modified nanoparticles10.1021/mp400216r ↗
56. Mannose-modified hyaluronic acid nanocapsules for the targeting of tumor-associated macrophage10.1007/s13346-022-01265-9 ↗
57. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review10.1016/S0168-3659(99)00248-5 ↗
58. Advanced NIR-II fluorescence imaging technology for precise evaluation of nanomedicine delivery in cancer therapy10.3390/chemosensors12060113 ↗
59. Targeted macrophage mannose receptor (CD206)-specific protein delivery via engineered extracellular vesicles10.1016/j.heliyon.2024.e40940 ↗
60. New perspectives in cell adhesion: RGD and integrins10.1126/science.2821619 ↗
61. Integrin alpha9beta1: unique signaling pathways reveal diverse biological roles10.4161/cam.4.2.10900 ↗
62. Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy10.1172/JCI159473 ↗
63. The relationship between expression of PD-L1 and HIF-1α in glioma cells under hypoxia10.1186/s13045-021-01102-5 ↗
64. Hypoxia-inducible factor-2α directly promotes BCRP expression and mediates the resistance of ovarian cancer stem cells to adriamycin10.1002/1878-0261.12419 ↗